Status:
COMPLETED
Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients
Lead Sponsor:
Alkarkh Health Directorate-Baghdad
Conditions:
IMMUNOTHERAPY
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Out of 49 early-stage critically-ill COVID-19 patients, 21 patients are the experimental group who take convalescent plasma compared to 28 patients receive only conventional therapy without taking Con...
Detailed Description
Objectives: The current COVID-19 pandemic needs unconventional therapies to tackle the resulted high morbidity and mortality. Convalescent plasma is one of the therapeutic approaches that might be of ...
Eligibility Criteria
Inclusion
- 49 critically-ill COVID-19 patients are included.
- All of the patients were with pneumonia and residing in RCU
- Age ≥ 18 y
- With dyspnea and oxygen saturation less than 90% in resting state.
- At their first 3 days in RCU either receiving O2 therapy, c-pap, or on ventilators.
- All of the patients were residing in infectious diseases wards before being transferred to RCU.
Exclusion
- The exclusion criteria of the COVID-19 patients were:
- Previous allergic history to plasma or its ingredients such as sodium citrate.
- Cases with serious general conditions, such as severe organ dysfunction, that are not suitable for transfusion.
- Very late stage of the acute respiratory distress (ARDS) where Convalescent plasma (CP) has proved to be of low therapeutic benefit
Key Trial Info
Start Date :
April 3 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2020
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT04441424
Start Date
April 3 2020
End Date
June 1 2020
Last Update
June 23 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Akarkh Healt hdirectorate
Baghdad, Iraq, 14222